Beta Drugs
Ticker > Company >

Beta Drugs share price

Beta Drugs Ltd.

NSE: BETA SECTOR: Pharmaceuticals & Drugs  1.24 L   215   14

1330.10
+24.80 (1.90%)
NSE: 30 Apr 4:00 PM

Price Summary

Today's High

₹ 1367.6

Today's Low

₹ 1300.1

52 Week High

₹ 2000

52 Week Low

₹ 990.1

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 1386.04 Cr.

Enterprise Value

₹ 1371.6 Cr.

No. of Shares

1.04 Cr.

P/E

89.82

P/B

7.38

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  180.29

CASH

₹ 141.99 Cr.

DEBT

₹ 127.55 Cr.

Promoter Holding

64.63 %

EPS (TTM)

₹  14.81

Sales Growth

11.43%

ROE

12.6 %

ROCE

13.53%

Profit Growth

-29.65 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year11.43%
3 Year20.82%
5 Year27.51%

Profit Growth

1 Year-29.65%
3 Year2.7%
5 Year16.8%

ROE%

1 Year12.6%
3 Year18.31%
5 Year17.36%

ROCE %

1 Year13.53%
3 Year22.91%
5 Year22.31%

Debt/Equity

0.9885

Price to Cash Flow

76.82

Interest Cover Ratio

5.3823

CFO/PAT (5 Yr. Avg.)

1.03111034612625

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2026 64.63 0.00
Dec 2025 64.90 0.00
Sep 2025 66.73 0.00
Jun 2025 66.73 0.00
Mar 2025 66.73 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 20.8218756428622% for the Past 3 years.
  • Company has been maintaining healthy ROCE of 22.9117333333333% over the past 3 years.
  • The company has an efficient Cash Conversion Cycle of 6.7407 days.
  • Company has a healthy liquidity position with current ratio of 3.8774.
  • The company has a good cash flow management; CFO/PAT stands at 1.03111034612625.
  • The company has a high promoter holding of 64.63%.

 Limitations

  • The company has shown a poor profit growth of 2.70052383722634% for the Past 3 years.
  • The company is trading at a high PE of 89.82.
  • The company is trading at a high EV/EBITDA of 36.4713.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2025
Net Sales 50.28
Total Expenditure 43.73
Operating Profit 6.55
Other Income 2.51
Interest 3.17
Depreciation 2.51
Exceptional Items 0
Profit Before Tax 3.37
Tax 0.12
Profit After Tax 3.25
Adjusted EPS (Rs) 3.21

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 79.46 124.85 157.87 197.62 220.2
Total Expenditure 64.15 99.66 126.68 164.1 188.78
Operating Profit 15.31 25.18 31.2 33.53 31.42
Other Income 0.61 0.86 1.04 1.73 6.19
Interest 0.77 0.41 0.84 1.05 4.76
Depreciation 5.27 5.47 6.19 4.72 7.44
Exceptional Items 0 0 0 0 -4.57
Profit Before Tax 9.88 20.16 25.21 29.48 20.84
Tax 2.9 5.92 6.39 7.55 5.41
Net Profit 6.98 14.25 18.82 21.94 15.43
Adjusted EPS (Rs.) 6.91 14.11 18.64 21.73 15.29

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 9.61 9.61 9.61 9.61 10.09
Total Reserves 53.8 67.85 86.64 106.4 118.94
Borrowings 3.39 5.15 3.73 3.62 123.8
Other N/C liabilities 1.45 1.84 1.69 2.36 5.06
Current liabilities 20.34 30.06 35.22 53.26 63.52
Total Liabilities 88.59 114.51 136.89 175.26 321.42
Assets
Net Block 28.01 34.06 34.77 36.48 53.48
Capital WIP 1.9 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 6.54 6.54 6.55 5.77 5.77
Loans & Advances 5.81 6.89 6.78 13.68 15.68
Other N/C Assets 0.05 0.05 0.05 0.05 0.18
Current Assets 46.28 66.97 88.74 119.27 246.3
Total Assets 88.59 114.51 136.89 175.26 321.42
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 9.88 20.16 25.21 29.48 25.41
Adjustment 4 3.11 0.42 -6.29 -7.55
Changes in Assets & Liabilities -2.28 -4.51 -15.41 -2.01 0.18
Tax Paid 0 0 0 0 0
Operating Cash Flow 11.6 18.76 10.23 21.19 18.04
Investing Cash Flow -3.15 -12.72 -5.82 -11.02 -21.46
Financing Cash Flow -4.34 1.27 -2.19 -0.76 118.2
Net Cash Flow 4.1 7.31 2.21 9.4 114.79

Corporate Actions

Investors Details

PARTICULARS Mar 2025% Jun 2025% Sep 2025% Dec 2025% Mar 2026%
promoters 66.73 66.73 66.73 64.90 64.63
aditi batra 0.01 0.01 0.01 0.01 0.01
heena batra 0.01 0.01 0.01 0.01 0.01
neeraj batra 65.96 65.96 65.96 64.13 63.86
rahul batra 0.41 0.41 0.41 0.41 0.41
varun batra 0.35 0.35 0.35 0.35 0.34
PARTICULARS Mar 2025% Jun 2025% Sep 2025% Dec 2025% Mar 2026%
investors 33.27 33.27 33.27 35.10 35.37
airavat capital trust - a... - - - 1.54 1.68
ashish kacholia 5.78 5.78 5.78 5.78 5.76
bsas infotech limited . - - - 1.27 1.31
llp 0.15 0.16 0.18 0.25 0.05
onkar singh 1.06 1.06 1.06 1.06 1.06
surendra kumar jain - - - - 1.02
suryavanshi commotrade pr... 6.74 6.74 6.74 6.74 6.71
bsas infotech limited 1.27 1.27 1.27 - -

Annual Reports

Title Link
Title Link
Annual Report 2020
Annual Report 2018

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
Research Nuvama Wealth
Research Edelweiss
Research NuvamaWealth
Research Nuvama
Research Nuvama Wealth

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
TYPE QUARTER Link
TYPE QUARTER Link
Presentation FY2024

Beta Drugs Stock Price Analysis and Quick Research Report. Is Beta Drugs an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Beta Drugs. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Beta Drugs has a PE ratio of 89.8151837021331 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Beta Drugs has ROA of 6.2142% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Beta Drugs has a Current ratio of 3.8774.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Beta Drugs has a ROE of 12.5952%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Beta Drugs has a Debt to Equity ratio of 0.9885 which means that the company has low proportion of debt in its capital.

  • Sales growth: Beta Drugs has reported revenue growth of 11.4254% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Beta Drugs for the current financial year is 14.2670930025744%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Beta Drugs is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Beta Drugs is Rs 14.8093. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Beta Drugs in Ticker for free. Also, one can get the intrinsic value of Beta Drugs by using Valuation Calculators, which are available with a Finology ONE subscription. 

Beta Drugs FAQs

Q1. What is Beta Drugs share price today?
Ans: The current share price of Beta Drugs is Rs 1330.1.

Q2. What is the market capitalisation of Beta Drugs?
Ans: Beta Drugs has a market capitalisation of Rs 1386.03841958 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Beta Drugs?
Ans: The PE ratio of Beta Drugs is 89.8151837021331 and the P/B ratio of Beta Drugs is 7.37772206383191, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Beta Drugs share?
Ans: The 52-week high share price of Beta Drugs is Rs 2000, and the 52-week low share price of Beta Drugs is Rs 990.1.

Q5. Does Beta Drugs pay dividends?
Ans: Currently, Beta Drugs does not pay dividends. Dividend yield of Beta Drugs is around 0%.

Q6. What are the face value and book value of Beta Drugs shares?
Ans: The face value of Beta Drugs shares is Rs 10, while the book value per share of Beta Drugs is around Rs 180.286. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Beta Drugs?
Ans: Beta Drugs has a total debt of Rs 127.550035287 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Beta Drugs?
Ans: The ROE of Beta Drugs is 12.5952% and ROCE of Beta Drugs is 13.533%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Beta Drugs a good buy for the long term?
Ans: The Beta Drugs long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Beta Drugs undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Beta Drugs appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Beta Drugs’s financials?
Ans: You can review Beta Drugs’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Beta Drugs
X